<DOC>
	<DOCNO>NCT00457249</DOCNO>
	<brief_summary>It well recognize old adult contract pertussis , suffer complication , unwittingly transmit close contact , may well include infant young receive primary series DTaP vaccination . ADACEL® vaccine currently license US person 11 - 64 year age , pertussis vaccine yet approve administration old adult . The widely use Td vaccine US , DECAVAC® , upper limit age indication . The purpose trial describe safety immunogenicity ADACEL® vaccine among individual ≥ 65 year age .</brief_summary>
	<brief_title>A Trial Evaluate Safety Immunogenicity ADACEL® Vaccine Persons 65 Years Age Older</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Ambulatory institutionalize . At least 65 year age time vaccination . Signed Institutional Review Board ( IRB ) approve informed consent form . Able attend schedule visit comply trial procedure . Exclusion Criteria : Any condition , opinion investigator , would pose health risk participant interfere evaluation vaccine . Serious chronic disease ( eg , cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric ) unstable , opinion investigator , might : interfere ability participate fully study ; interfere evaluation vaccine . Known suspected impairment immunologic function , include use immune suppressive medication ( eg , rheumatoid arthritis drug methotrexate ; cancer chemotherapy agent vincristine ) . Febrile illness within last 72 hour oral temperature ≥ 100.4°F ( ≥ 38°C ) time inclusion . Any history document tetanus , diphtheria pertussis disease . Known suspected receipt tetanus , diphtheria acellular pertussis contain vaccine within precede 5 year . Administration immune globulin blood product within last three month , systemic corticosteroid therapy ( prednisone equivalent ) 2 consecutive week within past 6 month . Systemic antibiotic therapy within 72 hour prior enrollment . Received vaccine , influenza vaccine , 30day period prior enrollment schedule receive vaccine , influenza vaccine , 35day period enrollment . For influenza vaccine , defer received 14day period prior enrollment schedule receive 14day period enrollment . Suspected known hypersensitivity vaccine component . Participation another interventional clinical trial 4 week precede enrollment planning participate another interventional clinical trial plan period study . Use alcohol drug manner may , opinion investigator , interfere subject 's ability comply trial visit procedure . Thrombocytopenia bleed disorder contraindicate intramuscular vaccination . Subject deprive freedom administrative court order , emergency setting , hospitalize without his/her consent , require legally authorize representative .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Pertussis</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Tdap</keyword>
</DOC>